EL7.AI
StocksMedium•30 March 2026•
1 min read

Boston Scientific's Watchman Device Shows Positive Results in CHAMPION-AF Trial

Key Facts

1The Watchman FLX device demonstrated effectiveness comparable to blood thinners in reducing stroke risk and death in AFib patients.
2The study showed a significant reduction in non-procedural bleeding risk with the Watchman implant.
3Boston Scientific plans to seek an expanded indication for the device as a first-line stroke risk reduction option.

Boston Scientific (BSX) has released positive data from its CHAMPION-AF clinical trial regarding the Watchman FLX device. The study demonstrated that the device is as effective as oral anticoagulants in reducing stroke and death risks for patients with atrial fibrillation. Notably, the trial showed a significant reduction in non-procedural bleeding risks compared to traditional blood thinner therapies. Following these results, Boston Scientific plans to seek an expanded indication for the device as a first-line treatment option for stroke risk reduction. This clinical success positions the company to capture a larger market share by offering a viable alternative to long-term medication. Analysts view this development as a significant long-term growth driver for the company's cardiology portfolio.